{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:10:21Z","timestamp":1791317421312,"version":"4.3.1"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2012,4,6]],"date-time":"2012-04-06T00:00:00Z","timestamp":1333670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0029828","type":"journal-article","created":{"date-parts":[[2012,4,7]],"date-time":"2012-04-07T15:58:16Z","timestamp":1333814296000},"page":"e29828","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":141,"title":["Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain"],"prefix":"10.1371","volume":"7","author":[{"given":"Nicholas M.","family":"Levinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,4,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia.","volume":"340","author":"CL Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","volume":"347","author":"GD Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"J Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"NP Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.","volume":"95","author":"P le Coutre","year":"2000","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"M Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.","volume":"110","author":"HM Kantarjian","year":"2007","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"NP Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"ref11","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.","volume":"63","author":"JM Golas","year":"2003","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V108.11.168.168","article-title":"A Phase 1\/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.","volume":"108","author":"J Cortes","year":"2006","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/jco.2010.28.15_suppl.6502","article-title":"Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).","volume":"28","author":"JE Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.","volume":"66","author":"M Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-08-0126","article-title":"SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.","volume":"7","author":"A Vultur","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref16","first-page":"106","article-title":"Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src\/Abl kinase inhibitor, in patients with advanced breast cancer.","author":"M Campone","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1110\/ps.051750905","article-title":"High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.","volume":"14","author":"MA Seeliger","year":"2005","journal-title":"Protein Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.str.2007.01.015","article-title":"c-Src binds to the cancer drug imatinib with an inactive Abl\/c-Kit conformation and a distributed thermodynamic penalty.","volume":"15","author":"MA Seeliger","year":"2007","journal-title":"Structure"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/0008-5472.CAN-08-3953","article-title":"Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.","volume":"69","author":"MA Seeliger","year":"2009","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1073\/pnas.0600048103","article-title":"Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.","volume":"103","author":"W Wang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","article-title":"Recent changes to the MOSFLM package for processing film and image plate data.","volume":"26","author":"AGW Leslie","year":"1992","journal-title":"Joint CCP4+ESF-EAMCB Newsletter on Protein Crystallography"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1107\/S0907444994003112","article-title":"The CCP4 Suite: programs for protein crystallography.","volume":"50","year":"1994","journal-title":"Acta Cryst, D"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution.","volume":"66","author":"PD Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.","volume":"66","author":"MA Young","year":"2006","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot.","volume":"66","author":"P Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1006\/jmbi.1999.2743","article-title":"Can anomalous signal of sulfur become a tool for solving protein crystal structures?","volume":"289","author":"Z Dauter","year":"1999","journal-title":"Journal of Molecular Biology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"11853","DOI":"10.1021\/jp002242r","article-title":"Vibrational Stark Effects of Nitriles I. Methods and Experimental Results.","volume":"104","author":"SS Andrews","year":"2000","journal-title":"J Phys Chem A"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1063\/1.1287343","article-title":"A liquid nitrogen immersion cryostat for optical measurements.","volume":"71","author":"SS Andrews","year":"2000","journal-title":"Review of Scientific Instruments"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","article-title":"Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.","volume":"44","author":"DH Boschelli","year":"2001","journal-title":"J Med Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.3390\/molecules15064261","article-title":"Synthesis of Bosutinib from 3-Methoxy-4-hydroxybenzoic Acid.","volume":"15","author":"XJ Yin","year":"2010","journal-title":"Molecules"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.","volume":"11","author":"CH Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.","volume":"277","author":"J Stamos","year":"2002","journal-title":"J Biol Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.","volume":"66","author":"JS Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"S Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity.","volume":"26","author":"MW Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.","volume":"28","author":"SA Wells Jr","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.","volume":"105","author":"CH Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1021\/jm000420z","article-title":"Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.","volume":"44","author":"DH Boschelli","year":"2001","journal-title":"J Med Chem"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.","volume":"289","author":"T Schindler","year":"2000","journal-title":"Science"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1073\/pnas.162140299","article-title":"Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.","volume":"99","author":"S Roumiantsev","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref42","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).","volume":"62","author":"B Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1371\/journal.pbio.0040144","article-title":"A Src-like inactive conformation in the abl tyrosine kinase domain.","volume":"4","author":"NM Levinson","year":"2006","journal-title":"PLoS Biol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase.","volume":"112","author":"B Nagar","year":"2003","journal-title":"Cell"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1073\/pnas.0811223106","article-title":"A conserved protonation-dependent switch controls drug binding in the Abl kinase.","volume":"106","author":"Y Shan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/384484a0","article-title":"Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation.","volume":"384","author":"H Yamaguchi","year":"1996","journal-title":"Nature"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1093\/emboj\/16.18.5572","article-title":"Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.","volume":"16","author":"SR Hubbard","year":"1997","journal-title":"EMBO J"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2174\/092986730609220401150028","article-title":"The structure-based design of ATP-site directed protein kinase inhibitors.","volume":"6","author":"LM Toledo","year":"1999","journal-title":"Curr Med Chem"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"12050","DOI":"10.1021\/bi0352926","article-title":"Vibrational Stark effects calibrate the sensitivity of vibrational probes for electric fields in proteins.","volume":"42","author":"IT Suydam","year":"2003","journal-title":"Biochemistry"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.1127159","article-title":"Electric fields at the active site of an enzyme: direct comparison of experiment with theory.","volume":"313","author":"IT Suydam","year":"2006","journal-title":"Science"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1021\/bi701708u","article-title":"Electrostatic fields near the active site of human aldose reductase: 1. New inhibitors and vibrational stark effect measurements.","volume":"47","author":"LJ Webb","year":"2008","journal-title":"Biochemistry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0029828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T21:06:12Z","timestamp":1687381572000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0029828"}},"subtitle":[],"editor":[{"given":"Ramani","family":"Ramchandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,4,6]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0029828","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,6]]}}}